21 June 2019
Diurnal Group plc
("Diurnal" or the "Company")
Change of Auditor
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, is pleased to announce that following the conclusion of a tender process overseen by the Company's audit committee, the Company has appointed PricewaterhouseCoopers LLP ("PwC") as the Company's independent auditor for the financial year ended 30 June 2019. The appointment of PwC as the Company's auditor for the financial year ended 30 June 2020 will be subject to approval by the Company's shareholders at the next Annual General Meeting due to be held in November 2019.
The Company's previous auditor, KPMG LLP, has confirmed to the Company that it is not aware of any circumstances connected with its termination as auditor that it considers should be brought to the attention of the Board, creditors or shareholders of the Company.
|
For further information, please visit www.diurnal.co.uk or contact: |
|
|
|
|
|
Diurnal Group plc |
+44 (0)20 3727 1000 |
|
Martin Whitaker, Chief Executive Officer |
|
|
Richard Bungay, Chief Financial Officer |
|
|
|
|
|
Panmure Gordon (UK) Limited (NOMAD and Joint Broker) |
+44 (0) 20 7886 2500 |
|
Corporate Finance: Freddy Crossley, Emma Earl |
|
|
Corporate Broking: James Stearns |
|
|
|
|
|
Cantor Fitzgerald Europe (Joint Broker) |
+44 (0)20 7894 7000 |
|
Corporate Finance: Philip Davies, William Goode, Michael Boot |
|
|
Healthcare Equity Sales: Andrew Keith |
|
|
|
|
|
FTI Consulting (Investor Relations) |
+44 (0)20 3727 1000 |
|
Simon Conway |
|
|
Victoria Foster Mitchell |
|
|
|
|
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
